---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018398"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:58:38.874992+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months

## Summary
- First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.
- Median overall survival of 17.8 months observed in 22 patients (95% CI lower bound 12.5 months) in third-line setting.
- Expansion includes two arms: ateganosine+cemiplimab (Libtayo) and monotherapy; screening in Europe/Asia.
- Regeneron supplies Libtayo for combination cohort.

## SEC filing metadata
- accession: 0001641172-25-018398
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/0001641172-25-018398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018398
- JSON: https://secwatch.observer/filing/0001641172-25-018398.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.